2024
A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults
Kao C, Rostad C, Nolan L, Peters E, Kleinhenz J, Sherman J, Tippett A, Shih J, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer E, Rouphael N, Anderson E. A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults. The Journal Of Infectious Diseases 2024, 230: 1093-1101. PMID: 38536442, PMCID: PMC11565884, DOI: 10.1093/infdis/jiae148.Peer-Reviewed Original ResearchHealthy US adultsDouble-blindThird dosePlacebo-Controlled Clinical TrialSystemic reactionsHepatitis E virus vaccineUS adultsHepatitis E vaccinePlacebo groupPlacebo-controlledAdverse eventsE vaccineSecond doseClinical trialsDay 1Immune responseDosePhase 1ImmunogenicityMonthsSafety studiesVaccineInfant mortalityTrialsAdults
2023
Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis
Liverman R, Serluco A, Nance G, George R, Rodriguez D, Deshpande S, Mao C, Garro R, Yildirim I. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation 2023, 27: e14493. PMID: 36945819, DOI: 10.1111/petr.14493.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric solid organ transplant recipientsCytomegalovirus DNAemiaValganciclovir prophylaxisDose reductionRisk factorsTransplant recipientsImpact of dose adjustmentsRisk factors associated with failureFactors associated with failureOrgan transplant recipientsHeart transplant recipientsIndependent risk factorRetrospective cohort studyAssociated with morbidityCMV DNAemiaCytomegalovirus eventsValganciclovir dosingImmunosuppressive therapyDose adjustmentYounger age groupsDNAemiaValganciclovirRisk stratificationAdverse events